Entrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) Director Peter S. Kim bought 2,600 shares of the firm's stock in a transaction that occurred on Monday, April 8th. The stock was bought at an average price of $13.57 per share, for a total transaction of $35,282.00. Following the completion of the acquisition, the director now directly owns 62,936 shares in the company, valued at $854,041.52. The transaction was disclosed in a legal filing with the SEC, which is available through this link.
Entrada Therapeutics Trading Down 5.7 %
Shares of TRDA stock opened at $12.52 on Thursday. Entrada Therapeutics, Inc. has a 1-year low of $10.62 and a 1-year high of $18.44. The company has a market capitalization of $420.67 million, a price-to-earnings ratio of -48.15 and a beta of -0.50. The stock's fifty day simple moving average is $13.54 and its 200-day simple moving average is $14.47.
Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) last issued its quarterly earnings results on Wednesday, March 13th. The company reported ($0.29) earnings per share for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.22). Entrada Therapeutics had a negative net margin of 5.18% and a negative return on equity of 2.89%. The business had revenue of $41.85 million for the quarter, compared to analysts' expectations of $27.82 million. On average, sell-side analysts predict that Entrada Therapeutics, Inc. will post -1.54 EPS for the current year.
Wall Street Analyst Weigh In
Claim Your Complimentary Bitcoin Reward
From Crypto Swap Profits | Ad
Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you?
In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants.
Absolutely no strings attached.
Secure Your Spot Now
A number of equities analysts recently issued reports on the company. Oppenheimer assumed coverage on Entrada Therapeutics in a report on Friday, January 5th. They issued an "outperform" rating and a $22.00 target price on the stock. HC Wainwright reiterated a "buy" rating and set a $20.00 price target on shares of Entrada Therapeutics in a report on Monday, March 18th.
Get Our Latest Report on TRDA
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently modified their holdings of TRDA. Price T Rowe Associates Inc. MD boosted its position in Entrada Therapeutics by 1.4% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 3,014,377 shares of the company's stock valued at $40,754,000 after purchasing an additional 42,327 shares during the last quarter. BlackRock Inc. boosted its position in Entrada Therapeutics by 563.2% during the second quarter. BlackRock Inc. now owns 1,405,806 shares of the company's stock valued at $21,284,000 after purchasing an additional 1,193,821 shares during the last quarter. Vanguard Group Inc. boosted its position in Entrada Therapeutics by 4.4% during the fourth quarter. Vanguard Group Inc. now owns 1,065,166 shares of the company's stock valued at $16,073,000 after purchasing an additional 44,849 shares during the last quarter. Wellington Management Group LLP boosted its position in Entrada Therapeutics by 2.6% during the third quarter. Wellington Management Group LLP now owns 1,045,652 shares of the company's stock valued at $16,521,000 after purchasing an additional 26,144 shares during the last quarter. Finally, FMR LLC boosted its position in Entrada Therapeutics by 7.8% during the second quarter. FMR LLC now owns 944,908 shares of the company's stock valued at $11,509,000 after purchasing an additional 68,114 shares during the last quarter. Hedge funds and other institutional investors own 86.39% of the company's stock.
Entrada Therapeutics Company Profile
(
Get Free Report)
Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
